MicroRNAs play important roles in post-transcriptional regulation of gene expression by inhibiting protein translation and/or promoting mRNA degradation. Importantly, biogenesis of microRNAs displays specific temporal and spatial profiles in distinct cell and tissue types and hence affects a broad spectrum of biological functions in normal cell growth and tumor development. Recent discoveries have revealed sophisticated mechanisms that control microRNA production and homeostasis in response to developmental and extracellular signals. Moreover, a link between dysregulation of microRNAs and human brain disorders has become increasingly evident. In this review, we focus on recent advances in understanding the regulation of microRNA biogenesis and function in neuronal and glial development in the mammalian brain, and dysregulation of the microRNA pathway in neurodevelopmental and neurodegenerative diseases. microRNAs, neuronal development, synaptic plasticity, oligodendroglial differentiation, brain tumor, neurodegenerative disorders
Molecular mechanisms that control biogenesis of microRNAs
MicroRNAs are short 18-25 nucleotide small non-coding RNA molecules that function to silence gene expression via sophisticated post-transcriptional regulation [1] . In mammals, the primary precursors of microRNAs (pri-microRNAs) are transcribed by RNA polymerase II (for details of microRNA biogenesis, see recent reviews [2, 3] ) and cleaved by the nuclear RNase III endonuclease, Drosha, along with its regulatory subunit DGCR8. As a result, characteristic 70-100 nucleotide stem-loop precursor microRNAs are generated (pre-microRNAs) in the nucleus, sometimes even derived from introns after RNA splicing [46] . Pre-microRNAs are exported to the cytoplasm by Exportin5 and further processed by the RNase III, Dicer, to produce mature microRNAs of short duplexes from the terminal loop. Besides this canonical pathway for microRNA biogenesis, emerging evidence indicates the existence of atypical mechanisms for transcription and processing of virally encoded pri-microRNAs that are closely related to transfer RNA (tRNA) biogenesis [7] , which in turn converge on the DICER-dependent pathway to generate mature viral microRNAs. Whether cellular orthologues for components in this atypical pathway exist or this is a viral-specific mechanism remains unknown. Moreover, the biogenesis and stability of specific microRNAs can be modulated by selective RNA-binding proteins (RBPs) that are not core components of the microRNA machinery. In particular, numerous RBPs were recently found to modulate microRNA processing. For example, RBP LIN28 suppresses the biogenesis of let-7 microRNA by binding to the terminal loop of pri-let-7, thereby blocking Drosha cleavage [8] . Interestingly, in cells lacking LIN28, the KH-type splicing regulatory protein (KHSRP, also known as KSRP) recog-nizes the terminal loop of let-7 and promotes its maturation by facilitating its association with Drosha in the nucleus or with Dicer in the cytoplasm [9] . In contrast, another canonical splicing regulator, heteronuclear ribonucleoprotein A1 (hnRNPA1), binds to the same sequence in the pri-let-7 terminal loop to repress Drosha-mediated processing [9] . In fact, many RBPs classically known for regulating premRNA splicing are now found to play crucial roles in modulating microRNA biogenesis.
The mature microRNA duplexes are incorporated into the RNA-induced silencing complex (RISC) consisting of Dicer, TRBP, and Ago proteins, in which one or both strands of a microRNA are presented to cognate binding sites, also called microRNA recognition elements (MREs), in the protein-coding mRNA(s) to form an RNA hybrid via imperfect complementary base pairing. MREs are often located in the 3′ untranslated regions (UTRs) of the target mRNAs [10] , although clear examples also demonstrate the capability for microRNAs to target the open reading frame of the target mRNA [1113] . A single microRNA has the potential to target hundreds of distinct mRNA molecules to suppress expression of the encoded protein. On the other hand, multiple microRNAs are predicted to act on the same mRNA and most likely synergistically function to suppress expression of the target. Overall, more than 50% of human mRNAs are predicted to be targets of microRNAs [14] . Multiple molecular mechanisms have been reported that underlie microRNA-mediated gene silencing, including block of cap-dependent translation initiation, shortening of the polyA tail length, and degradation of the target mRNAs [15] . Besides targeting mRNAs, the most recent discoveries have revealed a new model for microRNA function, in which specific microRNAs, represented by miR-709 and miR-107, can directly target microRNA biogenesis posttranscriptionally [16, 17] , demonstrating a functional hierarchy within the microRNA pathway. Moreover, RBPs play a role in activation or relief of microRNA repression. For example, HuR, an AU-rich element-binding protein, relieves the miR-122-mediated repression of CAT-1 mRNA by interfering with microRNA binding to the 3′-UTR of target mRNAs [18] . In contrast, repression of c-Myc mRNA by the let-7 microRNA is enhanced by the HuR binding to adjacent AREs [19] . This suggests that regulation of microRNA-mediated repression by RBPs is probably a widespread phenomenon.
Despite the ubiquitous presence and essential roles of the microRNA pathway in all cell types examined [20] , expression of microRNAs in response to external signals is highly dynamic at both spatial and temporal levels, which is an apparently important mechanism that governs cell growth and development [1] . Interestingly, microRNAs are particularly abundant in the brain. At least 60% of known microRNA species are detected in the adult brain [21] and many are drastically regulated during embryonic brain development [22] . Upon neural lineage specification, a subclass of microRNAs, represented by miR-9, miR-124, and miR-128, are specifically expressed in neurons and play pivotal roles in neuronal development and synaptic plasticity. In contrast, distinct microRNA species are preferentially expressed in glial lineages, which control normal glia cell proliferation and differentiation [2325] . Specifically, miR-219 and miR-338 are crucial for the development of oligodendroglia, the cell type responsible for myelination of neuronal axons to enable proper conductivity in the brain [23] . Besides cell type-specificity, particular microRNAs demonstrate unique patterns of regional and subcellular localization in the brain. For example, miR-218, miR-221, miR-222, miR-26a, miR-128a/b, miR-138, and let-7c are preferentially enriched in the hippocampus, while miR-195, miR-497, and miR-30b are found to be enriched in the cerebellum [21] . This regional specificity in microRNA expression reflects the different cell composition within various brain regions. miR-134 and miR-26a are relatively enriched in neuronal dendrites in which local protein synthesis underlies synaptic plasticity, the foundation for learning and memory [26, 27] . Consistent with the idea that microRNAs may be involved in modulating local protein synthesis, miR-200c, miR-339 and miR-332 are present in biochemical preparations that are enriched in synapses [28] . Examples of microRNAs in specific cell lineages and subcellular compartments are illustrated in Figure 1 .
Essential roles of microRNA pathways in distinct neural cell types
Because conventional deletion of the Dicer gene arrests microRNA processing and results in early embryonic lethality [29] , conditional knockout of Dicer, which is required for microRNA biogenesis, has been used extensively to examine the collective roles of microRNAs in specific tissues and cell types in mice. Elimination of Dicer in neural stem cells causes profound defects in embryonic brain development and lethality [30, 31] . Apoptosis and failures in developing specialized neuronal arborizations are common detrimental effects in distinct neuronal populations as a result of losing DICER function. In specific neuronal cell types, the loss of Dicer in mature dopaminergic neurons leads to a progressive loss of midbrain dopaminergic neurons and markedly reduced locomotion, which is reminiscent of human patients with Parkinson's disease [32] . Ablation of Dicer function in Purkinje neurons leads to Purkinje cell death, followed by cerebellar degeneration and the development of ataxia [33] . Moreover, conditionally inactivate Dicer in forebrain and hippocampal neurons results in changes in dendrite morphology, spine length, apoptosis, microcephaly, ataxia, and lethality by 3 weeks after birth [34] . The importance of microRNA biogenesis is further supported by the fact that haploinsufficiency of the microRNA processer, Dgcr8, also leads to altered plasticity Besides brain neurons, functional requirements of microRNA pathways are also demonstrated by conditional knockout of Dicer in specialized neural cells in the retina, cochlea, and olfactory bulb. In addition, loss of Dicer in distinct glial cell populations also severely affects the development and function of the nervous system, because of the crucial roles of glia in supporting and modulating neuronal function [38] . Specifically, Dicer deficiency in the oligodendroglia lineage and Schwann cells causes failures in myelination of the central and peripheral nervous system (CNS and PNS) respectively [24,25,3941] . Interestingly, mice that loose Dicer in astrocytic glia do not show severe defects until the age of five weeks, characterized by progressive ataxia, cerebellar degeneration and seizures, consistent with the critical role of astroglia in neurotransmitter abundance and modulation of synaptic function [42] . All these observations clearly demonstrated the profound global function of microRNA pathways in the nervous system. The functional impairment of the nervous system by conditional elimination of microRNA biogenesis in various neural cell types is summarized in Table 1 .
Specific microRNAs in neuronal development and synaptic plasticity
Several specific microRNAs have been found to have important effects on neuronal development via regulation of mRNA targets. For example, neuron-specific miR-124 promotes neuronal differentiation by directly targeting PTB, which encodes a global repressor for alternative pre-mRNA splicing in non-neuronal cells [43] . The miR124-dependent silencing of PTB in neural stem cells is an important mechanism that permits neuronal lineage establishment and neuronal differentiation. Antagonizing miR-124 results in sustained PTB expression and suppresses neuronal-specific alternative splicing, and severely attenuates neuronal differentiation [43] . In addition, miR-9* and miR-124 inhibit neural progenitor cell specific BAF53a and BAF45a respectively, reducing proliferation and inducing differentiation [44] . Moreover, expression of miR-9/9* and miR-124 (miR-9/9*-124) in human fibroblasts is sufficient to induce their conversion into neurons [45] . These studies indicate that neuronal-specific microRNAs have instructive roles in neural fate determination.
In addition to neural lineage development, proper synaptic strength and connectivity are a crucial prerequisite for the function of the brain. In mature neurons that are connected in sophisticated synaptic circuitry, a number of mature microRNA species are found in the dendrites and synapses where active protein synthesis occurs locally to govern synaptic plasticity and cognitive ability [28, 46] , suggesting a function of microRNAs in synaptic mRNA translation. Two profiling studies have identified dendriticenriched microRNAs by either laser capture microdissection of dendrites isolated from primary rat hippocampal neurons [27] or biochemical isolation of synaptosomes, a biological fraction enriched for synaptic terminals [47] . The presence of functional components of the microRNA pathway in- dendrites, including Dicer and Argonaute, as well as pre-microRNAs, further implicate the regulation of microRNA biogenesis [46] , in response to neuronal activity changes. Indeed, neuronal activity has a profound impact on all aspects of microRNA biogenesis and function. At the transcriptional level, membrane depolarization or application of the neurotrophin, BDNF, activate transcription of miR-132 by the well-known activity-regulated transcription factor CREB [60] , while, neuronal activity activates miR-134 transcription by the transcription factor MEF2 [26] . In contrast, the dendritically enriched miR-138 is specifically expressed in brain neurons, while its precursor pre-miR-138 is ubiquitously expressed, suggesting specific post-transcriptional processing of miR-138 in neurons [61] , although neuronal specific transacting factors that enable processing of pre-miR-138 are yet to be identified. Furthermore, emerging evidence has revealed rapid regulation of numerous microRNAs upon neuronal activation under specific neurotransmitter receptor-mediated synaptic signaling, most likely via regulating the abundance of the microRNA processing machinery [46] . Besides microRNA abundance, it is important to point out that an expanding number of reports demonstrate interplay between microRNAs and RBPs that act on the same mRNA targets to modulate microRNA activity [62] . The well characterized RBP, HuR, is translocat-ed to the cytoplasm upon stress, which relieves cationic amino acid transporter 1 (CAT1) mRNA from miR-122-mediated repression [18] . In addition, phosphorylation of the fragile X mental retardation protein, FMRP, was recently shown to promote the formation of an AGO2-miR125a inhibitory complex on PSD-95 mRNA, which is reversed upon mGluR-triggered dephosphorylation of FMRP [63] .
It is clearly demonstrated that activity-regulated microRNAs can control neuronal development and function. In a well characterized example, miR-132 induces formation of dendritic spines and increases the occurrence of miniature EPSCs by repressing expression of p250GAP, a GTPase activating protein that regulates the Rac1/PAK1 pathway [64] . In addition, miR-134 regulates dendrite growth by targeting RNA-binding protein, Pumilio2 [26] , and decreases dendritic spine size by repressing LIMK1, a kinase that promotes actin polymerization [65] . In contrast, miR-138 induces spine shrinkage by targeting depalmitoylation enzyme, APT1, and by activation of the RhoA-ROCK pathway [47] .
MicroRNAs in oligodendroglial differentiation and myelin formation
Oligodendroglia in the CNS produce multilamellar myelin sheaths wrapping around neuronal axons, which are essential for axonal protection and saltatory conduction of action potentials. Oligodendroglia progenitor cells are specified from neural stem/progenitor cells, which proliferate and differentiate, and ultimately migrate to interact with axons where they become mature oligodendrocytes to form myelin sheaths. Abnormal formation and/or maintenance of myelin sheaths impairs nerve conduction and leads to progressive axonal degeneration, which contributes to the etiology of several neurological disorders, including multiple sclerosis and schizophrenia. A rich and fast growing literature has demonstrated that many intrinsic and extrinsic regulators control myelinating cell differentiation in a spatiotemporally specific manner. MicroRNAs, as novel post-transcriptional regulators, act cooperatively with developmental signals to control oligodendrocyte differentiation and myelin formation. In vivo elimination of Dicer1, specifically in oligodendroglia, by Olig1, Olig2, or CNP promoter-directed expression of the Cre-recombinase causes severe dysmyelination and motor behavior deficits, characterized by tremors, ataxia and paralysis [24, 25, 58, 59] , demonstrating essential roles of microRNA pathways in oligodendrogliadependent CNS myelination. In fact, OL-specific Dicer mutants suffer from oxidative damage, inflammatory astrocytosis and microgliosis in the brain, which eventually leads to neuronal degeneration and shorter lifespans [39] . Recent microarray profiling studies identified specific microRNAs that are rigorously regulated during oligodendroglial differentiation [66] , supporting the idea that developmentally programmed microRNA expression governs oligodendroglial lineage development. Interestingly, the neuronal specific miR-9 is down-regulated during the transition from oligodendroglial progenitor cells that still maintain a certain plural potency to mature oligodendrocytes [23] . This suggests that miR-9 may play opposing roles in neuronal and glial lineage specification. Regarding functional microRNA species in oligodendroglia, several studies collectively demonstrate that miR-219 is a major microRNA necessary and sufficient to promote oligodendrocyte terminal maturation [24, 25] . miR-138 and miR-338 also belong to the same class that advances oligodendrocyte differentiation [25] . Mechanistically, these aforementioned microRNAs directly target and silence transcription factors that suppress oligodendroglial differentiation, including ZFP238, FoxJ3, Sox3, and Hes5 [24, 25] , as well as PDGF receptor alpha, which mediates PDGF signaling to maintain oligodendroglial progenitors [67] . Later on in mature oligodendrocytes, miR-219 is believed to target the elongation of very long chain fatty acids protein 7 (ELOVL7) to maintain lipids and redox homeostasis, which are necessary for supporting axonal integrity as well as for the formation of compact myelin. Considering the pivotal role of miR-138 in controlling neuronal dendritic spine morphogenesis [47] , whether miR-138 acts through shared mRNA targets in neurons and oligodendroglia or alternatively targets distinct downstream pathways, perhaps with the help of neuronal and/or glial specific factors, still remains elusive.
MicroRNAs in brain tumor development
Primary brain tumors, though relatively rare, are the cause of a disproportionate level of morbidity and mortality and have been the subject of increasingly intensive research over the past two decades. Glioma, the most common primary tumor of the adult CNS, develops from fundamental genetic alterations that cause the formation of a tumor stem cell population that divides without restriction to normal physiological biochemical signaling. Gliomas are classified based on the different glial cells types present, including ependymomas (ependymal cells), astrocytomas (astrocytes), oligodendrogliomas (oligodendrocytes) and glioblastoma multiforme (GBM), the most frequent and malignant primary brain tumor [68] . In contrast, medulloblastoma (MB) is the most common brain malignancy in children that arises from altered development of cerebellar progenitor cells [69] . MicroRNAs certainly play critical roles in cancer initiation, progression, and some of them could be considered as clinical biomarkers for cancer diagnosis, prognosis and prediction of therapeutic response [70] . Specifically, expression profiling studies have revealed extensive alteration of microRNAs in primary glioblastoma, suggesting that microRNAs may represent a new class of genes involved in 
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Upregulated in glioma Triggers malignancy [75] Upregulated in MB [76] miR-221/222 PUMA Upregulated in GBM Inhibits cell apoptosis [77] PTPμ Upregulated in GBM cell line Increases cell migration and growth [78] p27(Kip1) Upregulated in GBM Increases cell proliferation [79, 80] BIRC1 Upregulated in GBM Inhibits cell apoptosis [81] miR-17-92 CTGF Upregulated in GBM spheroid [82] Upregulated in MB [83, 84] miR-10b HOXD10 Upregulated in GBM Induces glioma cell invasion [85, 86] Bim/AP-2γ/p21/p16 Upregulated in glioma Contributes to glioma growth [87] miR-26a PTEN, RB1, and MAP3K2 Upregulated in GBM Facilitates gliomagenesis [88, 89] Anti-oncomicroRNAs miR-34a MAGE-A Downregulated in MB Confers chemosensitivity [90] SIRT1 Downregulated in p53-mutantglioma cell line U251
Inhibits cell growth, migration and invasion, induces apoptosis [91] c-Met, Notch-1/2 Downregulated in glioma/ GBM Inhibits cell proliferation, survival, migration and invasion [92, 93] miR-106a E2F1 Downregulated in glioma Suppresses proliferation and induces apoptosis [94] miR-124 SLC16A1 CDK6
Downregulated in MB Inhibited cell proliferation [95, 96] Downregulated in GBM Inhibited cell proliferation [97] miR-128 Bmi-1 E2F3a ARP5
Downregulated in GBM Inhibited cell proliferation [71, 98, 99] Bmi-1 Downregulated in MB Inhibited cell proliferation, promotes cellular senescence [100] miR-125b Bmf Downregulated in glioma Inhibited cell proliferation [101, 102] miR-199b-5p HES1 Downregulated in MB Inhibited cell proliferation [103] oncogenesis [104] . The dysregulated microRNAs in GBM could be characterized as oncomiRs or anti-oncomiRs through post-transcriptionally regulating oncogenes or anti-oncogenes, respectively (Table 2 ). In GBM, the dysregulation is characterized by the strong up-regulation of miR-221, accompanied by a much broader spectrum of down-regulated miRs, including miR-128, miR-181a, miR-181b, and miR-181c [104] . Interestingly, dysregulation of microRNAs in MBs is characterized by a somewhat overlapping microRNA population [105] , especially the predominant down-regulation of a class of neural microRNAs, suggesting a tumor growth-inhibitory function of these microRNAs. It is worth pointing out that besides serving as a biomarker for tumor development, some microRNAs appear to be drug targets. For example, in glioma, knockdown of miR-21 increased apoptotic activity, and sensitized cells to cytotoxic tumor therapy [106109]. In medulloblastoma, suppression of miR-21 impedes cell migration [76] . These pioneer studies support alternative promising strategies to treat brain tumors.
MicroRNAs in neurodevelopmental and neurodegenerative disorders
A rapidly growing literature has demonstrated that altered neuronal plasticity and morphology, as seen in neurodevelopmental disorders, may result from disruption of a common post-translational process that is under tight control by microRNAs [110] . Several intellectual disability syndromes, such as Fragile X syndrome, Rett syndrome, and Down's syndrome, have been linked to the microRNA pathway [110] . Fragile X syndrome, characterized by intellectual disability and autistic features, is caused by loss of function of the fragile X mental retardation protein (FMRP). FMRP is involved in the microRNA pathway through interaction with Dicer and Ago1 [111] and association with specific microRNAs [112] . Specifically, miR-125b and miR-132 have been shown to associate with FMRP in the mouse brain and they exert opposing effects on dendritic spine morphology and synaptic plasticity. Loss of FMRP ameliorates the microRNAs effects on spine morphology [112] . In addition, FMRP indirectly regulates miR-124 levels by interaction with the Dicer1-Ago1-complex in Drosophila [113] , suggesting FMRP may maintain proper levels of many microRNAs in neuronal development.
Rett syndrome is an X-linked neuro-developmental disorder caused by mutations in the transcriptional co-repressor methyl CpG-binding protein (MeCP2). Upregulation or downregulation of MeCP2 both lead to Rett-like syndrome in mouse, suggesting maintenance of MeCP2 levels in a narrow range is essential for normal brain development and function [114] . miR-132, a brain-enriched microRNA, has been shown to inhibit MeCP2 translation [115] . More interestingly, loss of MeCP2 leads to down-regulation of miR-132 by indirect mechanisms [115] . This negative feedback loop provides a mechanism for tight homeostatic control of MeCP2 expression [115] . Moreover, alterations in microRNA profiles in MeCP2-knockout mouse models reveal that up-regulated microRNAs are responsible for the decreases of BDNF and Irak1 [116, 117] , which are crucial players for normal brain development.
Parkinson's disease (PD) is characterized by the progressive neurodegeneration of dopaminergic neurons (DNs) in the substantia nigra, leading to tremors, rigidity, and bradykinesia [118] . Conditional knockout of Dicer in dopaminergic neurons results in Parkinson's disease-like phenotypes with or without cell loss [32, 43] , suggesting microRNAs regulate homeostatic states in dopaminergic neurons. Consistent with this view, miR-133b is significantly downregulated in midbrain tissue from patients with Parkinson's disease [32] . Further studies revealed that miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor, Pitx3 [32] . In addition, miR-7 reduces alpha-synuclein protein, the major component of Lewy bodies in sporadic PD, through binding the 3'-UTR of alpha-synuclein mRNA and protecting cells against oxidative stress [119, 120] . Furthermore, the reduction of miR-7 in the MPTP-induced PD model further supports the role of miR-7 in controlling alpha-synuclein levels [119] , which is critical for the neurodegenerative process in PD.
Finally, emerging evidence also reveals the involvement of microRNA malfunction in Alzheimer's disease (AD), a progressive neurological degenerative disorder caused by the accumulation of plaques formed of short -amyloid (A) peptides. These peptides arise from the proteolytic cleavage of the -amyloid precursor protein (APP), by a -secretase known as the -site APP-cleaving enzyme (BACE), and -secretase. BACE1, a rate-limiting step enzyme for A peptide production, is thought to be an important risk factor for sporadic AD. Importantly, a number of microRNAs exhibit abnormal expression levels in postmortem AD brain tissues compared to matched normal controls [121] , and many of the altered microRNAs in AD have been shown to regulate BACE1 [122124]. Moreover, APP levels are also known to be under the regulation of microRNAs [125128].
Concluding remarks and perspectives
The pivotal importance of microRNAs in normal development and function of the brain has been clearly demonstrated. The most recent discoveries begin to elucidate an integrated picture regarding the function of specific microRNA species in distinct neural cell lineages, in response to different stimulation cues, as well as with respect to dysregulated microRNAs in various neurological diseases and brain tumors. The changes of microRNA expression patterns can serve as informative biomarkers that indicate the functional status of a normal brain, as well as disease progression and prognosis in brain tumors, neurodevelopmental disorders, and neurodegenerative diseases. Given the crucial function of microRNAs in governing normal brain function and the marked dysregulation of microRNAs in brain diseases, the question of whether microRNA function can be manipulated to obtain therapeutic benefits is an intriguing possibility currently under rigorous investigation. To achieve this goal, understanding the molecular mechanisms that regulate microRNA biogenesis and activity, at epigenetic, transcriptional and post-transcriptional levels, especially by co-operation with selective RBPs in response to developmental and synaptic signals, is an important question that needs to be delineated by future studies. In addition, given the large number of mRNAs predicted to be regulated by microRNAs, a practical strategy that fully integrates identification and validation of microRNA target sites and biological changes of functional mRNA targets by the biological and disease signatures of microRNAs is urgently needed; this is apparently the next challenge. Manipulation of one microRNA might simultaneously restore the level of a large network of disease-related target genes, which seems to be a promising strategy of treatment.
